Proficio Capital Partners LLC Purchases New Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Proficio Capital Partners LLC bought a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,238 shares of the company's stock, valued at approximately $411,000. Proficio Capital Partners LLC owned about 0.07% of Fulgent Genetics as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Fulgent Genetics by 113.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company's stock valued at $7,346,000 after purchasing an additional 179,477 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Fulgent Genetics by 220.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 43,813 shares of the company's stock worth $952,000 after purchasing an additional 30,160 shares during the period. State Street Corp lifted its position in Fulgent Genetics by 1.4% during the third quarter. State Street Corp now owns 793,545 shares of the company's stock valued at $17,244,000 after buying an additional 10,868 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Fulgent Genetics in the third quarter worth about $215,000. Finally, Geode Capital Management LLC boosted its position in Fulgent Genetics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company's stock valued at $10,930,000 after buying an additional 13,320 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company's stock.

Remove Ads

Fulgent Genetics Stock Up 1.2 %

FLGT stock traded up $0.20 during mid-day trading on Friday, reaching $17.05. 526,520 shares of the stock traded hands, compared to its average volume of 243,515. The business has a 50-day moving average of $16.81 and a two-hundred day moving average of $18.71. The firm has a market capitalization of $526.27 million, a PE ratio of -3.09 and a beta of 1.54. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $25.11.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th. Piper Sandler reduced their target price on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th.

Insider Buying and Selling at Fulgent Genetics

In other Fulgent Genetics news, CFO Paul Kim purchased 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the transaction, the chief financial officer now directly owns 348,282 shares in the company, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 31.76% of the company's stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.